Introduction
Determination of prognosis in patients with acute pulmonary embolism (PE) is a challenging task. Several clinical scores have been developed to help physicians estimate patients' prognosis and identify potential candidates for home care (Table 1 ) [1] [2] [3] [4] . The best-validated clinical prognostic score for PE is the Pulmonary Embolism Severity Index (PESI) [1] . The PESI comprises 11 easily available variables and assigns patients into five risk classes of increasing risk of 30-day mortality. Patients in risk classes I and II have a low risk of 30-day mortality (2.2%) and are candidates for less costly outpatient care [5] . A simplified six-item version of the PESI (sPESI) is also available [2] . Patients with a point score of 0 are considered low risk and have a 30-day mortality of 1%. The Geneva Prognostic Score (GPS) consists of six clinical, laboratory and radiologic variables [3] . Patients with a score of ≤ 2 points have a low risk (2.2%) of a combined adverse outcome of death, recurrent venous thromboembolism (VTE) and major bleeding within 90 days [3] .
Recently, a novel prognostic score for PE, the Registro Informatizado de la Enfermedad TromboEmbolica (RIETE) score, has been developed [4] . Patients without any of nine clinical and laboratory factors have a low risk (< 1%) of a combined adverse outcome of death, recurrent PE or major bleeding within 10 days of the index event. Although the RIETE score had a higher discriminative power than the PESI and the sPESI for predicting the combined adverse outcome in the derivation study (c statistic 0.77 vs. 0.72 and 0.71, respectively), the RIETE score has not been externally validated to date. Furthermore, prediction models usually perform better than existing scores when validation is performed using the derivation sample [6, 7] .
We therefore aimed to externally validate the RIETE score and to directly compare its prognostic performance with the PESI, sPESI and GPS in a prospective multicenter cohort of elderly patients with acute PE.
Methods

Study sample
The study was performed between September 2009 and December 2013 as part of the SWiss venous Thromboembolism COhort (SWITCO65+), a prospective multicenter cohort study that assessed long-term medical outcomes in elderly patients with acute symptomatic VTE from nine Swiss university and non-university hospitals [8] . Consecutive patients aged 65 years or older with objectively diagnosed symptomatic VTE were identified in the in-and outpatient services of all participating study sites. In this study, we considered only patients with an objectively diagnosed acute PE (n = 687). The criteria used to establish the diagnosis of PE were a positive spiral computed tomography or pulmonary angiography, a high-probability ventilation-perfusion scan or a proximal deep vein thrombosis (DVT) documented by compression ultrasonography or contrast venography in patients with acute chest pain, new or worsening dyspnea, hemoptysis or syncope [9] .
Patients with catheter-related thrombosis, insufficient German or French-speaking ability, conditions incompatible with the follow-up (i.e. terminal illness or place of living too far away from the study center), the inability to provide informed consent (i.e. severe dementia) or previously enrolled in the cohort were excluded. The ethics committee at each participating center approved the study. All participants gave their informed consent. A detailed description of the study methods has been published previously [8] . 
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Baseline data collection
For all enrolled patients, baseline demographic information (age and sex) and clinical data were prospectively collected by medical record review by trained research nurses and recorded on standard data collection forms. The comorbid conditions (active cancer, heart failure, chronic lung disease and recent major bleeding), vital parameters (mental status, heart rate, systolic blood pressure, respiratory rate, temperature and arterial oxygen saturation), laboratory findings (platelet count and creatinine clearance) and imaging results (proximal DVT by compression ultrasonography or contrast venography) that constitute the RIETE score, PESI, sPESI and the GPS were abstracted as part of the medical record review. For all vital signs, the measurement most closely related in time to the diagnosis of PE was abstracted from patient charts.
Clinical prognostic scores
Based on patient demographics and baseline clinical data obtained by chart review, we calculated the RIETE score, PESI, sPESI and the GPS for each patient. For the RIETE score, creatinine clearance was calculated using the Cockcroft and Gault formula [10] . We used 'patients being confined to bed for > 72 h in the last 3 months' as a proxy variable for recent immobility, originally defined as non-surgical patients who were confined to bed with bathroom privileges for > 4 days in the 2 months before PE diagnosis [4] . Furthermore, we used 'major bleeding occurred during last 3 months' as a proxy variable for recent major bleeding, originally defined as major bleeding < 30 days before PE [4] . For the GPS, we used an oxygen saturation < 90% measured by pulse oximetry as a surrogate marker for a PaO 2 <8 kPa [3] . Finally, concomitant DVT was defined as asymptomatic or symptomatic proximal DVT diagnosed by ultrasound in the GPS derivation/validation study [3, 11] , whereas we used objectively confirmed symptomatic proximal DVT to define DVT.
Based on commonly accepted definitions, patients with a RIETE score < 1, PESI score ≤ 85 (risk classes I and II), sPESI score < 1 and a GPS score ≤ 2 were considered at low risk of adverse outcomes [1] [2] [3] [4] . All other patients were considered at higher risk of complications. Missing values were assumed to be normal, a strategy frequently used in the clinical application of clinical prognostic rules [1, 12] . In a sensitivity analysis, we assumed missing variables to be abnormal.
Study outcomes
The primary outcome was overall complications within 10 days, defined as overall mortality, recurrent PE or major bleeding. Secondary outcomes were 30-day overall mortality after the diagnosis of PE and overall complications at 90 days. Recurrent PE was defined as a new intraluminal filling defect on spiral computed tomography or pulmonary angiography, a cut-off of a vessel > 2.5 mm in diameter on pulmonary angiography, a new perfusion defect involving ≥ 75% of a lung segment with corresponding normal ventilation (i.e. high probability lung scan) or confirmation of a new PE on autopsy [1, 13] .
We defined major bleeding according to the definition of the International Society of Thrombosis and Haemostasis as a fatal bleeding, a symptomatic bleeding at critical sites (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or intramuscular with compartment syndrome), a bleeding with a reduction of hemoglobin ≥20 g L À1 or a bleeding leading to the transfusion of 2 units or more of packed red blood cells [14] .
We assessed outcomes using patient or proxy interviews, interview of the patient's primary care physician and/or hospital chart review. A committee of three blinded, independent clinical experts adjudicated all outcomes and classified the cause of death. Death was judged to be a definite fatal PE if it was confirmed by autopsy or if death followed a clinically severe PE, either initially or after an objectively confirmed recurrent event. Death in a patient who died suddenly or unexpectedly was classified as possible fatal PE. Final classification was made on the basis of the full consensus of the committee.
Statistical analyses
We performed pairwise comparisons of the proportions of patients classified as low risk by the four scores using McNemar's test and adjusted P-values using the Bonferroni correction. We described the proportion of 10-day and 90-day overall complications (overall mortality, recurrent PE or major bleeding) and overall 30-day mortality in low-risk vs. higher-risk patients for each score and in patients stratified by the RIETE score as a continuous quantitative risk scale. To determine the accuracy of each score in predicting 10-day and 90-day overall complications and 30-day overall mortality, we estimated sensitivity, specificity, positive and negative predictive values and likelihood ratios for higher-risk vs. low-risk patients. We assessed the discriminative power of each score to predict 10-day and 90-day overall complications and 30-day overall mortality by calculating the area under the receiver operating characteristic (ROC) curve. We performed a non-parametric test of the equality of the areas under the four curves. We determined the goodness of fit of the score points for 10-day and 90-day overall complications and 30-day mortality in a logistic regression model using the Pearson chi-squared test.
All analyses were performed using Stata 14 (Stata Corporation, College Station, TX, USA).
Results
Study sample
Of the 695 identified patients with an objectively confirmed acute PE who were initially enrolled in SWITCO65+, we excluded seven who refused the use of their data and one who withdrew from the study within 1 day of enrolment, leaving a final study sample of 687 patients with acute PE. The baseline characteristics are shown in Table 2 .
Comparison of outcomes
Overall, 12 patients (1.8%; 95% confidence interval [CI], 1.0-3.0%), 22 patients (3.2%; 95% CI, 2.1-4.8%) and 39 patients (5.7%; 95% CI, 4.2-7.7%) died within 10, 30 and 90 days, respectively. Seventeen patients (2.5%; 95% CI, 1.6-3.9%) suffered a major bleeding and one patient (0. The 10-day overall complications among low-risk patients were 1.9% (95% CI, 0.7-4.7%) for the RIETE score, 1.7% (95% CI, 0.7-4.2%) for the PESI, 1.6% (95% CI, 0.6-4.1%) for the sPESI and 2.9% (95% CI, 1.9-4.6%) for the GPS (Table 3) . At 90 days, overall complications among low-risk patients were 3.7% (95% CI, 1.9-7.2%) for the RIETE score, 3.8% (95% CI, 2.0-7.0%) for the PESI, 3.7% (95% CI, 1.9-6.8%) for the sPESI and 8.3% (95% CI, 6.4-10.7%) for the GPS (Table 3) . *Systolic or diastolic heart failure, left or right heart failure, forward or backward heart failure, or a known left ventricular ejection fraction of < 40%. †Chronic obstructive pulmonary disease, active asthma, lung fibrosis, cystic fibrosis or bronchiectasis. ‡Cancer requiring surgery, chemotherapy, radiotherapy or palliative care during the last 3 months before index pulmonary embolism. §Disorientation, lethargy, stupor or coma. ¶Patients being confined to bed for > 72 h in the last 3 months. **Objectively confirmed, symptomatic proximal deep vein thrombosis. † †Patients with at least one missing score variable.
Patients classified as low risk based on the RIETE score, PESI and sPESI had a very low 30-day overall mortality of 0.0% (95% CI, 0.0-1.8%), 0.4% (95% CI, 0.1-2.3%) and 0.0% (95% CI, 0.0-1.5%), respectively, whereas low-risk patients based on the GPS had a higher 30-day mortality of 2.0% (95% CI, 1.1-3.4%) (Table 3) . Overall, 30-day mortality was highest in higher-risk patients based on the GPS (13.9%; 95% CI, 7.7-23.7%) and lowest in higher-risk patients based on the RIETE score (4.7%; 95% CI, 3.1-7.0%). PE-related 30-day mortality was 0.0% among low-risk patients based on the RIETE score, PESI and sPESI, and 0.5% (95% CI, 0.2-1.4%) among low-risk patients based on the GPS.
When using the RIETE score as a continuous quantitative risk scale, complications within 10 days occurred in 1.9% (95% CI, 0.7-4.7%), 4.8% (95% CI, 2.6-8.6%), 3.2% (95% CI, 1.3-7.9%), 6.9% (95% CI, 3.0-15.3%) and 6.1% (95% CI, 2.4-14.6%) of patients with a point score of 0, 1, 2, 3 and ≥ 4, respectively ( Table 4) .
Comparison of predictive accuracy and discriminative power
All four scores were less accurate in predicting overall complications than in predicting mortality, especially at 10 days (Table 5 ). The RIETE score, the PESI and the sPESI all had a sensitivity of 85% for predicting 10-day overall complications, whereas the GPS had a sensitivity of only 33% (Table 5 ). The positive predictive values for 10-day overall complications were low (< 13%) and the negative predictive values were high (≥ 97%) for all scores ( Table 5 ). The positive and negative likelihood ratios were generally poor, except for the positive likelihood ratio of the GPS (3.49). Whereas the areas under the ROC curve for predicting 10-day overall complications varied from 0.60 for the RIETE score to 0.72 for the GPS (Fig. 1, Panel A) , the areas under the ROC curve for predicting 90-day overall complications were similar for all scores (0.68-0.70) (Fig. 1, Panel B) .
The RIETE score and the sPESI both had a sensitivity of 100% for predicting 30-day overall mortality, whereas the PESI had a sensitivity of 96% and the GPS a sensitivity of only 46% ( Table 5) . As for overall complications, the positive predictive values for 30-day mortality were low (< 14%) and the negative predictive values were high (≥ 98%) for all scores ( Table 5 ). The RIETE score, PESI and the sPESI showed a good negative likelihood ratio of 0.07 (95% CI, 0-1.04), 0.13 (95% CI, 0.02-0.87) and 0.06 (95% CI, 0-0.91), respectively, whereas the GPS had a poor negative likelihood ratio of 0.60 (95% CI, 0.41-0.88). The positive likelihood ratios were generally poor, except for the GPS (4.88). The discriminative power for predicting 30-day overall mortality was good (area under the ROC curve, 0.76-0.78) and did not significantly differ between the scores (P = 0.87) (Fig. 1, Panel C) .
The goodness of fit was adequate for all scores. When we assumed missing variables to be abnormal in a sensitivity analysis, the area under the ROC curve for predicting 30-day overall mortality and overall complications remained similar across all scores. CI, confidence interval; PE, pulmonary embolism. *Defined as death, major bleeding or recurrent pulmonary embolism, whichever occurred first.
Discussion
In our prospective multicenter cohort of elderly patients with acute PE, the RIETE and both PESI scores accurately identified patients at low risk of 30-day overall mortality, whereas the GPS was less accurate in identifying low-risk patients. All scores were less accurate in predicting overall complications, especially at 10 days. The RIETE score classified a lower proportion of patients as low risk than the other scores and had a somewhat lower discriminative power for 10-day complications, the outcome for which it was derived. In contrast to the PESI and the sPESI, which were derived as mortality prediction scores, the RIETE score was developed to predict 10-day overall complications because 'clinical care should be based on a broader set of medical outcomes than just mortality' [4] . It also has been argued that outcomes within 7-10 days may be more relevant to the hospital admission decision than outcomes within longer follow-up durations [15] . In the RIETE derivation study, the RIETE score had a statistically significantly better discriminative power for predicting 10-day overall complications than the PESI or the sPESI (area under the ROC curve, 0.77 vs. 0.72 and 0.71, respectively) [4] . Even though the RIETE score was specifically derived to predict 10-day overall complications, it had a lower area under the ROC curve (0.60) for predicting complications at 10 days than the PESI (0.67), sPESI (0.65) and GPS (0.72) in our sample. Of note, in the RIETE score derivation study only patients with a PESI risk class I were considered low brisk [4] , whereas in the PESI derivation and validation studies patients with risk classes I and II were considered to be at low risk [1, 5] .
Although the patients included in the RIETE derivation sample were younger than in our sample (mean age 67 years vs. median age of 75 years), they had a similar prevalence of cancer, chronic heart failure and lung disease, moderate to severe kidney impairment and an abnormal platelet count, and a higher prevalence of tachycardia, hypotension, hypoxemia, immobility and concurrent DVT [4] . The 10-day overall complications rate was 3.9% in both the RIETE sample and our study. Overall, our results confirm that a novel prediction model must prove its predictive performance in different patient populations and over different disease spectrums before CI, confidence interval. *Defined as death, major bleeding or recurrent pulmonary embolism, whichever occurred first. its use can be recommended [16] . Among the clinical scores evaluated in our study, the PESI remains the only clinical prognostic model for acute PE whose effectiveness and safety has been successfully validated in a randomized controlled trial [5] . The safety and efficacy of the sPESI and the Hestia criteria are currently evaluated in an ongoing multinational open-label randomized controlled trial (clinicaltrials.gov, identifier: NCT02811237).
As the RIETE score and the PESI both consist of 11 variables that are widely available at admission, there may not be any difference in user friendliness between the scores. The GPS, which requires venous ultrasonography and arterial blood gas analysis, is more difficult to use.
Our study has potential limitations. First, we used immobility and major bleeding within 3 months as proxy measures for recent immobility and major bleeding, which may have overestimated disease severity and decreased the prognostic performance of the RIETE score. Conversely, the fact that we included only symptomatic proximal DVT and not all proximal DVTs may have decreased disease severity as determined by the GPS. Second, for calculation of the four scores, missing variables were considered to be normal. However, the prevalence of missing values was low and when we assumed missing values to be abnormal, the results remained similar, confirming the robustness of our results. Third, because the model coefficients and intercept were not reported in the derivation study [4] , we could not calibrate the model. Finally, we have not carried out a specific a priori power calculation for this ancillary study of SWITCO65+. Thus, our study may not have sufficient power to compare the scores' discriminative power, especially for the prediction of 10-day overall complications.
In conclusion, we externally validated the RIETE score in elderly patients with acute PE. The RIETE score had a similar discriminative power to predict 30-day mortality to both PESI scores. All scores were less accurate in identifying patients at low risk of overall complications. As the RIETE score had a somewhat lower discriminative power for 10-day complications and classified a lower proportion of patients as low risk than the other scores, it may not offer a practical advantage over the PESI and sPESI. 
